Rapid Relief Begins With Enhanced Penetration to the Ocular Surface
- EYSUVIS, the first and only corticosteroid approved for Dry Eye, is loteprednol etabonate ophthalmic suspension 0.25%, formulated with AMPPLIFY® Drug Delivery Technology1
IS DESIGNED TO2,3:
ENHANCE OCULAR SURFACE
to the sites of ocular surface inﬂammation, the cornea and conjunctiva
~300 nm Diameter
EYSUVIS, with AMPPLIFY®, was specifically developed for the short-term treatment of Dry Eye
Mucus Can Interfere With the Ability of Drugs to Reach Ocular Tissue
The tear film protecting the eye’s surface can trap and eliminate traditional suspension eyedrops as the eyelid blinks. This process can limit the penetration of drugs to target ocular surface tissues when treating conditions in the front of the eye, such as Dry Eye.
AMPPLIFY® Drug Delivery Technology has been shown to improve delivery of loteprednol etabonate compared to traditional suspension eyedrops without AMPPLIFY®2*
*Data from preclinical studies. Clinical significance of preclinical data has not been established.
References: 1. Data on file. Kala Pharmaceuticals. Watertown, MA. 2. Schopf L, Enlow E, Popov A, et al. Ocular pharmacokinetics of a novel loteprednol etabonate 0.4% ophthalmic formulation. Ophthalmol Ther. 2014;3(1-2):63-72. 3. Popov A. Mucus-penetrating particles and the role of ocular mucus as a barrier to micro- and nanosuspensions. J Ocul Pharmacol Ther. 2020;36(6): 366-375.
Important Safety Information
EYSUVIS, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.
Warnings and Precautions:
Delayed Healing and Corneal Perforation: Topical corticosteroids have been known to delay healing and cause corneal and scleral thinning. Use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation. The initial prescription and each renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining.
Intraocular Pressure (IOP) Increase: Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, as well as defects in visual acuity and fields of vision. Corticosteroids should be used with caution in the presence of glaucoma. Renewal of the medication order should be made by a physician only after examination of the patient and evaluation of the IOP.
Cataracts: Use of corticosteroids may result in posterior subcapsular cataract formation.
Bacterial Infections: Use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, corticosteroids may mask infection or enhance existing infection.
Viral Infections: Use of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular corticosteroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).
Fungal Infections: Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid application. Fungus invasion must be considered in any persistent corneal ulceration where a corticosteroid has been used or is in use.
The most common adverse drug reaction following the use of EYSUVIS for two weeks was instillation site pain, which was reported in 5% of patients.
EYSUVIS is a corticosteroid indicated for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.